RxDoctor Payments DataLook up a doctor →

Ying Peng, MD

Neurodevelopmental Disabilities · Ladera Ranch, CANPI 1528156429

Payments from drug & device makers

$18,337in general payments, 2019–2025

Across 740 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Tris Pharma Inc$1K
  • AstraZeneca$995
  • Neurelis, Inc.$799
  • Supernus Pharmaceuticals, Inc.$793
  • Argenx US, Inc.$749
  • plus $11K from 48 others

What the payments were for

  • Food & beverage$18,20499%
  • Education$1331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,337 in reported general payments places this provider in the 80th percentile of 21 neurodevelopmental disabilities providers in California.

See all neurodevelopmental disabilities providers in California

Medicare billing

Part B allowed, 2024
$62,845
Medicare patients
29
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4621$498,905
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$310,164
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5020$282,761
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$281,115
BriviactBrivaracetam23$36,245
Clonazepam13$227
Sodium Chloride0.9 % Sodium Chloride15$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$694$310,16414 claims
Bio Products Laboratory USA, Inc.Gammaplex$17$282,76120 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$414$281,11511 claims
UCB, Inc.Briviact$3,041$36,24523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 neurodevelopmental disabilities providers in California.

Other neurodevelopmental disabilities in Ladera Ranch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →